Estimates Revisions Damora Therapeutics, Inc.
Stocks
DMRA
KYG2646Y1044
Biotechnology & Medical Research
|
Real-time Estimate
Cboe BZX
14:40:54 2026-10-08 EDT
|
5-day change | 1st Jan Change | ||
| 20.58 USD | +1.70% |
|
+1.51% | -10.76% |
| 09-20 | Damora Therapeutics, Inc.(NasdaqCM:DMRA) added to S&P Global BMI Index | CI |
| 08-10 | Damora Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | - | - | ||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- DMRA Stock
- Consensus Damora Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
